At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 5 enrolled
Drug / intervention
Mature dendritic cell (DC) vaccine +2 morebiological
Likely dose
Cyclophosphamide 300mg/m^2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mature Dendritic Cell Vaccination Against Mutated Antigens in Patients With Advanced Melanoma
In Brief
A Phase 1 clinical trial evaluating Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, and 1 other intervention for Melanoma. Completed, enrolled 5 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartMay 2017
Primary CompletionMar 2023
TodayJul 2026
First PostedMar 28, 2017
Enrollment StartMay 1, 2017
Primary CompletionMar 31, 2023
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 9.3 years ago
Interventions
Mature dendritic cell (DC) vaccinebiological
Mature DC 7.5-15 million/peptide followed by 2 booster every six weeks of 1-5 million/peptide followed by standard of care anti PD-1 therapy.
Cyclophosphamide 300mg/m^2drug
administered prior to subject's first DC dose
Pembrolizumabdrug
administered 7-8 weeks after subject's last DC dose